Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240014/S001

MAGiC Ablation Catheter

Stereotaxis, Inc. · Decision date Jul 31, 2026

FDA DECISIONP240014/S001

What did the FDA approve?

FDA records P240014/S001 as a supplement to PMA P240014, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Jul 31, 2026.

FDA approval order statement

approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P240014.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Cardiovascular
Decision date
Jul 31, 2026
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P240014/S001
Regulatory pathway
PMA supplement
Product code
LPB
Decision code
APPR
Decision date
Jul 31, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Cardiac ablation percutaneous catheter.

Product code
LPB
FDA device class
3

For the original device and its historical approval scope, see PMA P240014. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240014 · Original PMA

    MAGiC Ablation Catheter

  2. P240014/S001 received

    Application receipt date recorded by FDA.

  3. P240014/S001 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P240014. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240014

Product / regulatory recordCompanyPathwayDecision dateSource
Stereotaxis, Inc.PMA approvalJan 5, 2026FDA

Explore the linked device profile

Other records with product code LPB

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Stereotaxis, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
710 Tucker Blvd., Suite 110, Saint Louis, MO, 63101

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records